

Scottish Post Menopausal Chemo-Endocrine Trial

Submission date 19/08/2002	Recruitment status No longer recruiting	☐ Prospectively registered ☐ Protocol
Registration date 19/08/2002	Overall study status Completed	☐ Statistical analysis plan ☐ Results
Last Edited 11/01/2016	Condition category Cancer	☐ Individual participant data ☐ Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr - -

Contact details
UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London
United Kingdom
NW1 2DA

Additional identifiers

Protocol serial number
BR9402

Study information

Scientific Title
Scottish Post Menopausal Chemo-Endocrine Trial

Study objectives
Not provided at time of registration

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Primary study design

Interventional

Study design

Randomised controlled trial

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Breast cancer

Interventions

Following surgery patients are randomised to one of two treatment groups:

1. Group A: Tamoxifen 20 mg daily for 5 years
2. Group B: Tamoxifen 20 mg daily for 5 years plus six cycles of CMF (cyclophosphamide, methotrexate, 5-fluorouracil) chemotherapy

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Tamoxifen

Primary outcome(s)

Not provided at time of registration

Key secondary outcome(s)

Not provided at time of registration

Completion date

30/09/2000

Eligibility**Key inclusion criteria**

1. Histologically confirmed invasive carcinoma of the breast
2. Post-menopausal
3. Aged <70 years
4. No medical contraindications to treatment

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

Female

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

01/01/1995

Date of final enrolment

30/09/2000

Locations**Countries of recruitment**

United Kingdom

England

Study participating centre

MRC Clinical Trials Unit

London

United Kingdom

NW1 2DA

Sponsor information**Organisation**

Scottish Cancer Therapy Network (UK)

Funder(s)**Funder type**

Research organisation

Funder Name

Scottish Therapy Network (UK)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration